Silver Book Fact

Because the resource use and direct cost of glaucoma treatment and management increases as the disease severity worsens– from an average $623 per early-stage patient to $2,511 per late-stage patient– a glaucoma treatment that delays the disease progression could significantly reduce its economic burden.

Lee P, Walt J, Doyle J, Kotak S, et al. A Multicenter, Retrospective Pilot Study of Resource Use and Costs Associated with Severity of Disease in Glaucoma. Archives of Ophthalmology. 2006; 124(1): 12-9. http://archopht.ama-assn.org/cgi/content/abstract/124/1/12

Reference

Title
A Multicenter, Retrospective Pilot Study of Resource Use and Costs Associated with Severity of Disease in Glaucoma
Publication
Archives of Ophthalmology
Publication Date
2006
Authors
Lee P, Walt J, Doyle J, Kotak S, et al.
Volume & Issue
Volume 124, Issue 1
Pages
12-9
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Intensive glucose control (3 or more daily insulin injections or continuous subcutaneous insulin infusion) reduced the mean risk of retinopathy progression by 54% in type 1 diabetes patients with minimal-to-moderate…  
  • Increase in AMD risk for people with a high dGI
    A recent study showed that there was a 49% increase in the risk of advanced AMD for people with a dGI (dietary glycemic index) higher than the sex median (women…  
  • Because the resource use and direct cost of glaucoma treatment and management increases as the disease severity worsens– from an average $623 per early-stage patient to $2,511 per late-stage patient–…  
  • Screening and treatment for eye disease in all type 2 diabetes patients would result in an estimated net savings of 94,304 person-years of sight.  
  • Anti-VEGF Visual Improvement
    Nearly 50% of DME patients who received an anti-VEGF drug, experienced substantial visual improvement after a year of injections.